(19)
(11) EP 2 651 937 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
13.07.2016 Bulletin 2016/28

(45) Mention of the grant of the patent:
11.05.2016 Bulletin 2016/19

(21) Application number: 11805574.8

(22) Date of filing: 14.12.2011
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
A61K 31/4745(2006.01)
A61P 17/06(2006.01)
A61P 17/04(2006.01)
A61P 31/12(2006.01)
A61P 31/04(2006.01)
 A61K 31/4188(2006.01)
A61P 11/06(2006.01)
A61P 37/08(2006.01)
A61P 17/12(2006.01)
A61P 31/18(2006.01)
A61P 1/16(2006.01)
(86) International application number:
PCT/GB2011/052474
(87) International publication number:
WO 2012/080728 (21.06.2012 Gazette 2012/25)

(54)

IMIDAZO[4,5-C]QUINOLIN-1-YL DERIVATIVE USEFUL IN THERAPY

IMIDAZO-[4, 5 -C]-CHINOLIN-1-YL-DERIVAT FÜR DIE THERAPIE

DÉRIVÉ IMIDAZO[4,5-C]QUINOLIN-1-YLE UTILE EN THÉRAPIE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 16.12.2010 US 423644 P

(43) Date of publication of application:
23.10.2013 Bulletin 2013/43

(73) Proprietor: Sumitomo Dainippon Pharma Co., Ltd.
Osaka-shi Osaka 541-8524 (JP)

(72) Inventors:
  • MCINALLY, Thomas
    Macclesfield, Cheshire SK10 4TG (GB)
  • PIMM, Austen
    Macclesfield, Cheshire SK10 4TG (GB)

(74) Representative: Vossius & Partner Patentanwälte Rechtsanwälte mbB 
P.O. Box 86 07 67
81634 München
81634 München (DE)


(56) References cited: : 
WO-A1-2008/135791
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).